Press Release

CREATIVE DIAGNOSTICS ANNOUNCES THE LAUNCH OF ITS HIGHLY SENSITIVE KANAMYCIN ELISA KIT FOR PRECISE ANTIBIOTIC DETECTION



Creative Diagnostics Announces the Launch of Its Highly Sensitive Kanamycin ELISA Kit for Precise Antibiotic Detection

FOR IMMEDIATE RELEASE

24/04/2024

Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, is pleased to announce the launch of its cutting-edge Kanamycin ELISA Kit. This innovative kit enables the rapid and accurate detection of kanamycin residues in various biological products.

Biopharmaceuticals are a class of drugs that are typically produced in living organisms and can be used to treat a wide range of diseases. Biopharmaceutical samples include hormones, enzymes, monoclonal antibodies, vaccines, and blood factors, each of which face different challenges during drug development and production, including process-related residual impurities and their levels in the final biopharmaceutical product.

The use of appropriate concentrations of antibiotics during cell culture can prevent contamination as well as morphological or physiological changes caused by contamination. In addition, certain antibiotics are used to screen transfected/transgenic cells. Therefore, antibiotics are common cell culture-derived impurities in biomanufacturing processes.

Kanamycin or Kanamycin A is a bactericidal aminoglycoside antibiotic available in oral, intravenous and intramuscular forms for the treatment of a wide range of infections and tuberculosis. Kanamycin is isolated from Streptomyces kanamycinensis and its most commonly used form is kanamycin sulfate. It is commonly used as an antibiotic in cell culture processes. Due to the potent effects of kanamycin on humans during the manufacturing process and in the finished drug product, regulatory agencies around the world have limited and quantified kanamycin residues. Residues of kanamycin during the manufacture of biologics can cause abnormal reactions in humans and therefore strict MRLs have been established.

Creative Diagnostics now provides researchers with a rapid, accurate, and easy-to-use method for detecting kanamycin residues in biological products. The analytical sensitivity of the Kanamycin ELISA kit has been determined to be 0.5 ng/mL. The standards / linear graph range is 0.5-40.5 ng/mL. It allows precise measurement of Kanamycin levels in various samples and can greatly reduce the operator error in the detection process.

This ELISA kit has been designed for the detection of Kanamycin based on the principle of the “indirect competitive” enzyme immunoassay. The microtiter plate is coated with a capture antigen linked to BSA. Kanamycin in the sample competes with the antigen on the microplate for antibodies. After addition of the enzyme conjugate, chromogenic substrate is used and the signal is measured by spectrophotometer. The absorbance is inversely proportional to the concentration of kanamycin in the sample. It is noted that this kit is for research and laboratory use only and is not intended for diagnostic, therapeutic, drug, home or other usage.

Creative Diagnostics offers Kanamycin ELISA Kit for the quantitative and qualitative analysis of kanamycin residues in biological samples. For more information on the new product, please visit https://www.creative-diagnostics.com/Kanamycin-ELISA-Kit-3589-464.htm.

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers’ assay development and manufacturing needs.

Tags:
Kanamycin ELISA Kit  |  Creative Diagnostics  |  

---

Organisation Profile:
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. We provide contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. Our goal is to be a trusted source for all your assay development and manufacturing needs.






Press release contact details for Creative Diagnostics

NameCreative Diagnostics
Tel
Fax
Email
Websitehttps://www.creative-diagnostics.com/
OrganisationCreative Diagnostics
Address
Town
County0
Postcode11967




Other press releases from Creative Diagnostics

Creative Diagnostics Launches HPV L1 Antibodies for Neutralization and Vaccine Development
Creative Diagnostics Introduces TCID50 Assay Service for Determining Viral Titers
Creative Diagnostics Introduces ELISA Kit Development Services to Support IVD Research
Creative Diagnostics Introduces Microneutralization Assay Service for Virus Detection
Creative Diagnostics Introduces Virus Yield Reduction Assay Service
Creative Diagnostics Introduces New Low Endotoxin Antibodies for Researchers
Creative Diagnostics Announces Calprotectin Reagents for Inflammatory Disease Research
Creative Diagnostics Introduces Viral Replicon Assay Service to Support Virology Research
Creative Diagnostics Announces the Launch of Radial Immunodiffusion Testing Service
Creative Diagnostics Launches Highly Specific Antibodies Against FXIIIa/F13A1 for Vascular Diseases
Creative Diagnostics Introduces qPCR Assay for Rapid Virus Detection and Quantification
Creative Diagnostics Launches New Reagent Solutions for Herpesvirus Research
Creative Diagnostics Announces New Reagents for Bioanalysis of Antibody Drug Conjugates
Creative Diagnostics Announces New Antimicrobial Susceptibility Testing Services
Creative Diagnostics Introduces New ELISA Kits to Accelerate Autoimmunity Research
Creative Diagnostics Launches Antimicrobial Synergy Testing Services
Creative Diagnostics Launches New Azaperone Test Reagents for Research Applications
Creative Diagnostics Launches Checkerboard Assay Services
Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facilitate NALFIA Development
Creative Diagnostics Announces New CLDN6 Solutions for Cancer Research
Creative Diagnostics Launches Minimum Inhibitory Concentration Testing Services
Creative Diagnostics Launches Carbamazepine Test Reagents
Creative Diagnostics Launches Macrophage Migration Inhibitory Factor Reagents for Research Applications
Creative Diagnostics Announces New Test Reagents for Dapsone
Creative Diagnostics Announces New MBC Assay for Antibacterial Testing Read more: https://www.digitaljournal.com/pr/news/getnews/creative-diagnostics-announces-new-mbc-assay-for-antibacterial-testing#ixzz8KcL65cji
Creative Diagnostics Announces New MBC Assay for Antibacterial Testing
Creative Diagnostics Launches Rapid Robenidine Test Reagents for the Analysis of Anticoccidial Residues
Creative Diagnostics Announces MDT Services for Measuring Antibacterial Effectiveness
Creative Diagnostics Launches New P53 and TP53 Antibodies for Cancer Research
Creative Diagnostics Launches Aflatoxin Test Reagents to Ensure Food Safety
Creative Diagnostics Launches Serum Plate Agglutination Test for In Vitro Detection of Multiple Pathogens
Creative Diagnostics Announces New AAV Reagent Solutions for Gene Therapy
Citrinin Test Reagents for Food Safety
Creative Diagnostics Announces Novel Agar Gel Precipitin Tests for Viral Antigen Detection
Creative Diagnostics Introduces Cutting-Edge Anti-AAV Antibody ELISA Kits for Gene Therapy Research
Creative Diagnostics Announces the Launch of Its Highly Sensitive Kanamycin ELISA Kit for Precise Antibiotic Detection
Creative Diagnostics Launches Comprehensive ELISA Based Assays for Vaccine Development
Creative Diagnostics Announces Comprehensive Vomitoxin Test Reagents for Food Safety Applications

Disclaimer:
Issuers of the press releases are solely responsible for the content of their press releases. Connect2business.co.uk cannot be held liable for the content posted by others to this website.